Svas Biosana SpA
MIL:SVS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Svas Biosana SpA
MIL:SVS
|
IT |
|
Swisscom AG
SIX:SCMN
|
CH |
|
Molson Coors Beverage Co
NYSE:TAP
|
US |
|
Fomento de Construcciones y Contratas SA
MAD:FCC
|
ES |
|
Xperi Holding Corp
LSE:0M2A
|
US |
|
Banco Santander SA
MAD:SAN
|
ES |
|
Subsea 7 SA
OSE:SUBC
|
UK |
|
Barclays PLC
LSE:BARC
|
UK |
|
MPLX LP
NYSE:MPLX
|
US |
|
Kingdom Holding Company SJSC
SAU:4280
|
SA |
|
Milestone Pharmaceuticals Inc
NASDAQ:MIST
|
CA |
|
Kroger Co
NYSE:KR
|
US |
Wall St Price Targets
SVS Price Targets Summary
Svas Biosana SpA
According to Wall Street analysts, the average 1-year price target for SVS is 17.44 EUR with a low forecast of 17.27 EUR and a high forecast of 17.96 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is SVS's stock price target?
Price Target
17.44
EUR
According to Wall Street analysts, the average 1-year price target for SVS is 17.44 EUR with a low forecast of 17.27 EUR and a high forecast of 17.96 EUR.
What is the Revenue forecast for Svas Biosana SpA?
Projected CAGR
10%
Over the last 5 years, the compound annual growth rate for Revenue has been 10%. The projected CAGR for the next 3 years is 10%.
What is the Operating Income forecast for Svas Biosana SpA?
Projected CAGR
11%
Over the last 5 years, the compound annual growth rate for Operating Income has been 15%. The projected CAGR for the next 3 years is 11%.
What is the Net Income forecast for Svas Biosana SpA?
Projected CAGR
15%
Over the last 5 years, the compound annual growth rate for Net Income has been 19%. The projected CAGR for the next 3 years is 15%.
